Antibe Therapeutics (CVE: ATE OTCQB: ATBPF) CEO Dan Legault joined Steve Darling from Proactive Vancouver to share details about how the company is dealing with the Pandemic crisis and if they are seeing any effect on their Phase 2 study with their lead drug, ATB-346. Legault also told Proactive about their other drug, this one for post-surgery pain, ATB-352 and what the next steps are in its development
Full interview: Antibe Therapeutics finishes Phase 2 trial for ATB-346; results expected in weeks
Quick facts: Antibe Therapeutics Inc
Price: 4.85 CAD
Market Cap: $220.71 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE